Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb 10;2(2):1000277.
doi: 10.4172/2155-6113.1000277.

Are Serotonin Alterations the Link between Thrombocytopenia and Poor Immune Status among HIV Infected Individuals?

María José Míguez-Burbano  1 , Allan Rodriguez  2 , Mayra Vargas  1 , Gabriella Tantalean  1 , Ranjini Valiathan  3 , Wenyaw Chan  4
Affiliations

Are Serotonin Alterations the Link between Thrombocytopenia and Poor Immune Status among HIV Infected Individuals?

María José Míguez-Burbano et al. J AIDS Clin Res. .

Abstract

Objective: Thrombocytopenia (TCP<150 × 103 cells/mm3) has emerged as a relevant factor in the clinical course of HIV. However, the mechanisms mediating such observations have not been well characterized, limiting the possibility of creating targeted interventions. Notably, platelets are the storage and transporter system for serotonin and Brain derived neurotrophic factor (BDNF), which recent laboratory studies associated with viral replication and lymphocyte survival. Thus, we posit that (1) TCP will be associated with reduced levels of BDNF and serotonin (2) That these alterations will lead to poor viro-immune responses to antiretroviral therapy.

Methods: To achieve this goal, a total of 400 people living with HIV were consecutively enrolled to characterize the frequency of thrombocytopenia in hazardous and non-hazardous alcohol user populations in the HAART era. Then, participants underwent immune and laboratory assessments, to determine if TCP was associated with alterations in serotonin (5-HT) and brain derived neurotrophic factor (BDNF).

Results: The prevalence of thrombocytopenia in this antiretroviral treated cohort was 14%. Rates were significantly higher in the heavy alcohol users, HAU versus the non HAU group (Heavy: 25% versus HAU: 15% versusnon-HAU: 10%). Multivariate model analyses indicated that having TCP, low BDNF levels (<5000 pg/ml), and number of drinks per day were predictors of serotonin levels. PLWH with TCP had about 2-fold lower PPP-BDNFlevels (5037.4 ± 381 vs. 9137.5 ± 7062 pg/ml p=0.0001). Other significant predictors of BDNF levels at the last visit included receiving selective serotonin reuptake inhibitors and PPP serotonin levels. Multivariate analyses also confirmed that altered serotonin levels were associated withhigh viral loadsboth low CD4 cell counts.

Conclusions: Thrombocytopenia is a relatively frequent complication of HIV, andis particularly prevalent among hazardous alcohol users (HAU). These findings suggest that TCP is associated with altered levels of BDNF and serotonin, suggesting that they may be the bridge linking TCP and poor viro-immune responses observed in this group. These results could have important clinical and therapeutic implications.

Keywords: Alcohol; BDNF; HIV/AIDS; Serotonin; Thrombocytopenia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Proposed Model.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Burbano X, Miguez MJ, Lecusay R, Rodriguez A, Ruiz P, et al. Thrombocytopenia in HIV-infected drug users in the HAART era. Platelets. 2001;12:456–461. - PubMed
    1. Miguez MJ, Burbano X, Archer H, Shor-Posner G. Limited impact of highly active antiretroviral therapy in thrombocytopenia. J Acquir Immune Defic Syndr. 2002;30:260–261. - PubMed
    1. Pearce CL, Mack WJ, Levine AM. Thrombocytopenia is a strong predictor of all-cause and AIDS-specific mortality in women with HIV: The women’s interagency HIV study. Blood. 2004;104:569A–570A.
    1. Vannappagari V, Nkhoma ET, Atashili J, Laurent SS, Zhao H. Prevalence, severity, and duration of thrombocytopenia among HIV patients in the era of highly active antiretroviral therapy. Platelets. 2011;22:611–618. - PubMed
    1. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ciesielski CA. Surveillance for thrombocytopenia in persons infected with HIV: results from the multistate Adult and Adolescent Spectrum of Disease Project. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:374–379. - PubMed

LinkOut - more resources